retatrutide clinical trials review trial results 2024 2025 press release A of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Lilly's triple agonist, retatrutide, delivered – A New Obesity Drug Delivered
Pay in 4 interest-free payments of $5.60 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25





/afaqs/media/media_files/2026/01/08/lilly-2026-01-08-18-10-57.png)

















